Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

SpringWorks plans $115M IPO re ex-Pfizer drugs

SpringWorks Therapeutics has filed to raise $115 million in an IPO. The money will take SpringWorks through to regulatory filings for two former Pfizer drugs against...

| By Kelley Gipson

Cara licenses Enteris oral formulation technology

Cara Therapeutics has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to Enteris’ Peptelligence® Technology. “We are pleased to...

| By Kelley Gipson

JAX steps up fight re opioids and rare diseases

Independent nonprofit biomedical research institute The Jackson Laboratory (JAX) has teamed with Lovelace Biomedical, Exemplar Genetics, Iontox and the University of Pennsylvania to win a...

| By Kelley Gipson

SpringWorks appoints Frank Perier CFO

SpringWorks Therapeutics has appointed Francis (Frank) Perier, Jr. as Chief Financial Officer (CFO). Mr. Perier previously served as the CFO of Forest Laboratories, Inc. for...

| By Kelley Gipson

BI and Anderson Cancer form virtual R&D center

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for...

| By Kelley Gipson

Rallybio in joint venture with UK firm

The Farmington biotech startup Rallybio reports it is working on drug discovery with Exscientia an artificial intelligence company in the United Kingdom. Steve Uden, chief...

| By Kelley Gipson

Achillion provides corporate update

“We continued to advance our complement factor D inhibitors in the second quarter of 2019 by efficiently executing on our global development and regulatory strategies,...

| By Kelley Gipson

Shoreline Bio expands international distribution

Shoreline Biome has announced partnerships with six international distributors. The distributors will sell the company’s microbiome kits and other products to companies and research organizations in...

| By Kelley Gipson

Tangen awarded 2nd phase re anthrax contract

The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) awarded Tangen Biosciences, Inc. the second phase of a contract...